The global Methylphenidate Market experienced robust growth in the year 2021 and is poised to maintain a high Compound Annual Growth Rate (CAGR) throughout the forecast period. This surge in demand can be attributed to the increasing utilization of methylphenidate in the field of psychiatry, specifically for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This condition, characterized by attention and impulsivity issues, has witnessed a rise in diagnoses, particularly among children and adolescents. Furthermore, methylphenidate has found application in the management of narcolepsy, a sleep disorder that causes excessive daytime drowsiness. Its stimulating properties make it effective in reducing sleepiness and promoting wakefulness in individuals suffering from narcolepsy.
Methylphenidate is classified as a central nervous system stimulant, and it plays a crucial role in stabilizing moods through controlled-release formulations, typically in tablet or capsule form. This medication consists of phenylamine and is categorized as a controlled substance due to its potential for misuse and the production of euphoric sensations. As such, it is legally available only with a prescription, often sold under generic brand names like Ritalin (Novartis International AG, Switzerland) and Concerta (Janssen Pharmaceuticals Inc., Belgium). Its usage is not limited to ADHD but extends to narcolepsy, making it an essential therapeutic option for individuals battling excessive daytime sleepiness, which, in severe cases, can lead to hallucinations and sleep paralysis.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5717
Factors Driving Global Methylphenidate Market Growth:
- Increasing Mental Health Disorders: The prevalence of mental health disorders and neurological issues has been steadily rising, creating a heightened demand for psychiatric medications like methylphenidate. The Centers for Disease Control and Prevention (CDC) reported in 2016 that over 6.1 million children in the U.S. had been diagnosed with ADHD, with a substantial number among students aged 13-17. The consistent use of social media and consumption of short-form digital content have contributed to decreasing attention spans, leading to behavioral disorders in teenagers. These disorders, if left untreated, can result in self-isolation, school dropout, and depression, all of which drive the demand for medications, thus contributing to market growth.
- Treatment of Narcolepsy: Methylphenidate's efficacy in treating narcolepsy has opened up new opportunities for market players. This sleep disorder is characterized by extreme daytime drowsiness and sleep attacks. The medication acts as a stimulant, reducing excessive sleepiness by promoting non-rapid-eye-movement (non REM) sleep. With the daily stressors and lifestyle factors contributing to sleep disorders, the demand for methylphenidate in treating narcolepsy is expected to increase, making it a promising market opportunity.
- Type 1 Segment Growth: Among the various types of narcolepsy, the type 1 segment is expected to experience significant growth during the forecast period. Type 1 narcolepsy is characterized by cataplexy, sudden muscle weakness while awake, and is prevalent in nearly 30 patients among 10,000 individuals. Controlled-release tablets are highly beneficial in such cases, as they release the medication gradually, providing a stabilizing effect in psychiatric conditions. This widespread usage in type 1 narcolepsy drives market revenue growth in this segment.
- ADHD Segment Growth: The segment dedicated to Attention Deficit Hyperactivity Disorder (ADHD) is expected to witness substantial revenue growth during the forecast period. ADHD, often referred to as Attention Deficit Disorder (ADD), is increasingly diagnosed in children and teenagers. Research indicates that this disorder affects up to 28.9% of children, with a majority of cases found in male teenagers. The rise in social anxiety, exacerbated by online education during the COVID-19 pandemic, has further fueled ADHD diagnoses.
Regional Insights:
- North America: The North American region is expected to dominate the global methylphenidate market in terms of revenue share. This can be attributed to the presence of large pharmaceutical companies, easy access to manufacturing facilities, and the increasing incidence of mental health disorders. In the United States alone, nearly 9.4% of children were diagnosed with ADD, as per the 2016 CDC survey. Canada is also witnessing a rise in cases of ADD, with methylphenidate being extensively prescribed for its treatment. Major pharmaceutical players like Pfizer Inc., Purdue Pharma L.P., and Mylan N.V. further bolster the production of such medications, contributing to the region's market dominance.
- Europe: The European region is poised to lead in terms of revenue growth, driven by increasing medical research, the presence of prominent pharmaceutical companies, and a growing number of healthcare facilities. Despite being underdiagnosed in many cases, mental health disorders are on the rise in Europe. The continent has a history of ADHD affecting over 4.6% of children and adolescents, a figure that is expected to increase in 2022. Leading pharmaceutical giants such as Novartis International AG, Union Chimique Belge S.A., and Sandoz facilitate increased production. With robust manufacturing capacities, Europe continues to be a leader in market revenue growth.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5717
Key Market Players:
Several major companies play a pivotal role in the global methylphenidate market, including Pfizer Inc., Sandoz, Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKlein Plc., Mylan N.V., Impax Laboratories Inc., Union Chimique Belge S.A., Eli Lilly and Company, Purdue Pharma L.P., and Dr. Reddy's Laboratories.
Strategies and Objectives:
- In April 2021, the U.S. Food and Drug Administration approved Adhansia XR, a drug based exclusively on methylphenidate, produced by a subsidiary of Purdue Pharma L.P. This approval extended its use to children as young as 6 years old, increasing the availability of medication in pediatric psychiatry.
- In September 2020, Dr. Reddy's Laboratories launched controlled-release methylphenidate tablets as a generic ADHD medicine in the U.S. market. This strategic move facilitated the company's expansion into North America and streamlined the supply of this essential drug.
Market Segmentation:
The global methylphenidate market is segmented based on type, application/end use, and region.
Type:
- Type 1
- Type 2
Application/End Use:
- Attention Deficit Hyperactivity Disorder
- Narcolepsy
- Others
Regional Outlook:
- North America (U.S., Canada, Mexico)
- Europe (Germany, UK, France, Italy, Spain, BENELUX, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
- Latin America (Brazil, Rest of Latin America)
- Middle East Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East Africa)
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5717
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Genital Warts Treatment Market
Myofascial Pain Syndrome Market
Proteus Syndrome Treatment Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
